End of trials

A third study presented by Erik van Lieshout, MD, the Netherlands, examined the effect of the doctor-nurse to be qualified by intensive care ambulance transportation. The researchers prospectively assigned patients in intensive care to be made by the physician or transport of the teams led by nurses and used the data stored digital surveillance to determine whether patients had critical events during transport. They found that groups led by the transport nurses had results that matched the conduct medical groups, suggesting that, at least among the less severely ill critical nurse-led transportation is a safe choice.The results of the C91 ‘Late-Breaking Clinical Trials’ on the afternoon of Tuesday, May 17 will bring new perspectives of clinical problems and potential treatments. While examining five possible new therapies for people with asthma , emphysema, lymphangioleiomyomatosis , pulmonary tuberculosis and chronic obstructive pulmonary disease , a sixth research the safety of medical counter-transport team led by nurses critically ill patients.

Three months survival of these patients was 38 percent compared to 87 percent of patients who did not develop renal failure (p <0... Finally, a study by Richard Albert, MD, Denver Health, has examined the reduction in the frequency of exacerbations of COPD with a macrolide antibiotic, azithromycin, taken daily for a year in addition to usual treatment. The treatment significantly reduced the frequency of exacerbations and improving quality of life, but caused decreases in open court in a small fraction of patients. Another study presented by Susan Dorman, MD, of Johns Hopkins University, examined the effectiveness of rifampicin in the treatment against tuberculosis, rifapentine. The researchers found that rifapentine administered without food was safe and generally well tolerated as rifampicin, and seemed to be the most effective. In one, researchers in Australia have identified a way for pregnant women with asthma to prevent exacerbations. This randomized controlled trial tested an algorithm for the management of asthma during pregnancy is based on the fraction of exhaled nitric oxide that indicates the level of inflammation and symptoms, and compared to a standard Directive-based care. They measured FeNO, symptoms and lung function during monthly visits. For women randomized to treatment algorithm based on eNO has been used to increase or decrease their ICS medication.

Long-acting beta agonists have been used to treat symptoms when FENO was not high.